CS
PTGX icon

Credit Suisse’s Protagonist Therapeutics PTGX Stock Holding History

Credit Suisse’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.82M Buy
63,024
+507
+0.8% +$13.8K ﹤0.01% 1914
2023
Q4 		$1.43M Buy
62,517
+12,404
+25% +$217K ﹤0.01% 2106
2023
Q3 		$836K Sell
50,113
-12,721
-20% -$247K ﹤0.01% 2394
2023
Q2 		$1.74M Buy
62,834
+24,833
+65% +$621K ﹤0.01% 2010
2023
Q1 		$874K Buy
38,001
+6,764
+22% +$114K ﹤0.01% 2411
2022
Q4 		$341K Sell
31,237
-795
-2% -$6.71K ﹤0.01% 2973
2022
Q3 		$270K Buy
32,032
+217
+0.7% +$2.05K ﹤0.01% 3122
2022
Q2 		$251K Sell
31,815
-1,083
-3% -$13.1K ﹤0.01% 3239
2022
Q1 		$779K Buy
32,898
+4,550
+16% +$128K ﹤0.01% 2702
2021
Q4 		$969K Buy
28,348
+653
+2% +$20.6K ﹤0.01% 3342
2021
Q3 		$491K Buy
27,695
+240
+0.9% +$10.2K ﹤0.01% 3810
2021
Q2 		$1.23M Buy
27,455
+6,215
+29% +$205K ﹤0.01% 3229
2021
Q1 		$549K Sell
21,240
-29,583
-58% -$749K ﹤0.01% 3705
2020
Q4 		$1.02M Buy
50,823
+23,347
+85% +$502K ﹤0.01% 3328
2020
Q3 		$537K Buy
+27,476
New +$516K ﹤0.01% 3349
2016
Q4 		– Sell
-16,924
Closed -$358K – 4199
2016
Q3 		$358K Buy
+16,924
New +$231K ﹤0.01% 3590

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Credit Suisse's PTGX Position: Q1 2024 in Review

Credit Suisse increased its Protagonist Therapeutics (PTGX) stake by 0.81% in Q1 2024, buying an estimated $13.8K and bringing the position to 63,024 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1914.

Credit Suisse first reported a position in PTGX in Q3 2016 and has held it in 16 quarters since. 185 funds tracked by Wall St. Rank hold PTGX as of Q1 2024.

  • Credit Suisse held 63,024 shares of Protagonist Therapeutics worth $1.82M as of Q1 2024.
  • Credit Suisse bought 507 Protagonist Therapeutics shares in Q1 2024, an estimated $13.8K.
  • Protagonist Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1914 holding.
  • Credit Suisse first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 16 quarters since.
  • 185 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.